| abstract |
The invention relates to a combination which comprises a first active ingredient which is a vasculostatic compound and a second active ingredient which decreases the activity of the epidermal growth factor (EGF), in particular, for the delay of progression or treatment of a disease associate d with deregulated angiogenesis, especially a proliferative disease; a pharmaceutical composition comprising such a combination; a commercial packa ge comprising such a combination as a combined preparation; and to a method of treatment of a warm-blooded animal, especially a human. |